Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
In a small, controlled study of 18 people with treatment-resistant major depression, a single intravenous dose of the NMDA receptor antagonist ketamine (0.5 mg/kg) produced rapid drops in depression scores. Improvement began within about 2 hours and remained statistically significant compared with placebo for up to 1 week. The study…
The endocannabinoid system (ECS) is a widespread brain signaling system made of cannabinoid receptors, naturally made lipid messengers, and the enzymes that make and break those messengers. The two best-studied messengers are 2-AG and anandamide, and they are produced and degraded by different enzyme pathways. CB1 receptors are common in…
Compass Pathways reported early results from its first Phase 3 trial of synthetic psilocybin (COMP360) for treatment‑resistant depression. In 258 patients, the 25 mg dose showed a statistically significant improvement versus placebo on the MADRS depression scale at week 6 (a 3.6‑point difference, p < 0.001). The Data and Safety…
This review describes the endocannabinoid system (ECS) as a widespread network of natural cannabinoids, cannabinoid receptors (mainly CB1 and CB2), and the enzymes that make and break those chemicals. The ECS helps shape brain development and adjusts how neurons communicate. The authors note that THC is the main psychoactive part…
Researchers gave different psychedelic drugs to mice and found the drugs could reopen a window of brain plasticity used for learning social rewards. This reopened window went along with changes in a social hormone system in a key reward area of the brain and with changes in genes that control…
This review looks at studies about classic psychedelics (like LSD, psilocybin, and DMT/ayahuasca) and their effects on neuroplasticity — the brain’s ability to change. Animal studies show these drugs can raise genes tied to plasticity and cause dendrite and synapse growth. Human results are mixed, especially when studies use blood…
Researchers ran two fMRI studies using a gambling task to see how personality and a dopamine gene relate to brain reward signals. Rewards were given either right after a response (Study 1) or after a 7.5-second wait (Study 2). The studies found that people’s extraversion scores and whether they carried…
This 2014 review explains that the brain’s reward system — especially a region called the striatum — responds not only to things like food or money but also to social outcomes such as praise. The authors summarize many studies showing that the striatum carries signals when people evaluate social rewards,…
The authors reviewed psychedelic-assisted psychotherapy studies published from 1993 to 2017 to see how many people of color took part. They found 18 studies with about 280 people. About 82% of participants were non-Hispanic White, while only small percentages were African American, Latino, Asian, indigenous, or mixed race. Because so…
This paper reviews genetic studies that link several genes to higher risk for ADHD. It says problems in the brain's reward system—especially low dopamine activity—may make people seek things that raise dopamine. The authors propose that these gene variants form a “reward deficiency syndrome” (RDS) that may include ADHD, and…
This observational study followed 98 people who microdosed psychedelics over six weeks and found that people reported better psychological functioning on days they took a microdose, but there was little evidence that those effects lasted into the next days. Among 63 people who completed formal tests before and after the…
This paper describes psychedelic-assisted psychotherapy, which means giving drugs like ketamine, MDMA, psilocybin, LSD or ibogaine together with guided therapy. The authors say this approach has shown promising safety and benefits so far, even for people who did not get better with usual treatments. They also argue that these therapies…
